John McCormack, Ph.D.
Professor Emeritus of Pharmacology
Research Program: Clinical Research
VCC Membership Level: Member Scientist
Contact Information
B322 Health Science Research Facility
149 Beaumont Avenue
University of Vermont
Burlington, VT 05405
ph: (802) 656-4494
f: (802) 656-4523
John.McCormack@uvm.edu
Biography
Dr. McCormack earned a Ph.D. in pharmacology at Yale University in 1964. His post-doctoral research was completed in the laboratory of Professor Adrien Albert at the John Curtin School of Medical Research, Australian National University, Canberra, Australia. He joined the faculty of the UVM College of Medicine in 1966 and attained his current rank of full professor in 1975. Dr. McCormack has served on the Developmental Therapeutics and the Cancer Biology-Immunology Committees of the National Cancer Institute and on a Scientific Advisory Committee (Chemotherapy and Hematology) of the American Cancer Society. He also has served on the Research and Clinical Investigations Committee of the American Cancer Society and on review commitees of the National Center for Complementary and Alternative Medicine. His research activities have been supported by grants and contracts from the National Institutes of Health, the American Cancer Society and other organizations.
Research
Dr. McCormack's primary research interests have been in the medicinal chemistry and pharmacokinetics of compounds under development as chemotherapeutic agents for use in cancer and certain viral diseases. Among the types of compounds investigated in his laboratory are nitrogen heterocyclic compounds of the azanapthalene type and modified oligodeoxynucleotides. Recent research activities include the development and application of novel chemical and biochemical methods for the analysis of anticancer and antiviral drugs.
Recent Publications
Branda RF, Powden C, Brooks E, Yildirim Y, Naud S, McCormack JJ: Effects of Vitamin E and St. John's Wort on Chemotherapy-Induced Leukopenia in Rats. Translational Research,148; 315-324 (2006)
Other Key Publications
Hale JT, Bigelow JC, Mathews LA, McCormack JJ. Analytical and pharmacokinetic studies with 5-chloro-2\'-deoxycytidine. Biochem Pharmacology, 64:1493-502 (2002)
Branda RF, Chen Z, Brooks E, Naud S, Trainer T, McCormack JJ: Diet modulates the toxicity of cancer chemotherapy in rats. J. Lab. Clin. Med, 140: 358-368, (2002)
Howard OMZ, Oppenheim JJ, Hollingshead MG, Covey JM, Bigelow J, McCormack JJ, Buckheit RW, Jr., Clanton DJ, Turpin JA, Rice WG: Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: A candidate for chemotherapeutic and microbicidal application. J. Med. Chem., 41:2184-2193 (1998)
Jeong L-S, Buenger G, McCormack JJ, Cooney DA, Hao Z, Marquez VE: Carbocyclic analogues of the potent cytidine deaminase inhibitor 1-(β-D-Ribofuranosyl)-1,2-dihydropyrimidin-2-one (Zebularine). J. Med. Chem., 41:2572-2579 (1998)
Branda RF, Moore AL, Mathews L, Hong R, Zon G, Brown T, McCormack JJ: Amplification of antibody production by phosphorothioate oligodeoxynucleotides. J. Lab. Clin. Med. 128:329-338 (1996)
Rosowsky A, Mofa CE, Wright JE, Freisheim JH, Heusner JJ, McCormack JJ, Queener SF. 2,4-Diaminothieno(2,3-d)pyrimidine analogs of trimetrexate and piritrexem as potential inhibitors of P. carinii and T. gondii dihydrofolate reductase. J. Med. Chem. 1993 36: 3103-3112.
Branda RF, Moore AL, Mathews L, McCormack JJ, Zon G. Immune stimulation by an antisense oligomer complementary to the REV gene of HIV. Biochem. Pharmacol. 1993 45: 2037-2043.
Barchi JJ, Haces A, Marquez VE, McCormack JJ. Inhibition of cytidine deaminase by derivatives of 1-ribofuranosyl-dihyropyrimidine-2-one. Nucleosides & Nucleotides. 1992 11: 1781-1785.
